Fragment-based discovery of focal adhesion kinase inhibitors.
Gradler, U., Bomke, J., Musil, D., Dresing, V., Lehmann, M., Holzemann, G., Greiner, H., Esdar, C., Krier, M., Heinrich, T.(2013) Bioorg Med Chem Lett 23: 5401-5409
- PubMed: 23973211 
- DOI: https://doi.org/10.1016/j.bmcl.2013.07.050
- Primary Citation of Related Structures:  
4K8A, 4K9Y, 4KAB, 4KAO - PubMed Abstract: 
Chemically diverse fragment hits of focal adhesion kinase (FAK) were discovered by surface plasmon resonance (SPR) screening of our in-house fragment library. Site specific binding of the primary hits was confirmed in a competition setup using a high-affinity ATP-site inhibitor of FAK. Protein crystallography revealed the binding mode of 41 out of 48 selected fragment hits within the ATP-site. Structural comparison of the fragment binding modes with a DFG-out inhibitor of FAK initiated first synthetic follow-up optimization leading to improved binding affinity.
Organizational Affiliation: 
Merck KGaA, Merck Serono Research, Darmstadt, Germany. ulrich.graedler@merckgroup.com